BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21459059)

  • 1. Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin's lymphoma treated with rituximab-containing regimens.
    Pellicelli AM; Zoli V
    Dig Liver Dis; 2011 Jun; 43(6):501-2. PubMed ID: 21459059
    [No Abstract]   [Full Text] [Related]  

  • 2. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens.
    Marignani M; Mangone M; Cox MC; Angeletti S; Veggia B; Ferrari A; di Fonzo M; Begini P; Gigante E; Laverde G; Aloe-Spiriti A; Monarca B; Delle Fave G
    Dig Liver Dis; 2011 Feb; 43(2):139-42. PubMed ID: 20554488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy.
    Nosotti L; D'Andrea M; Pitidis A; Pimpinelli F; Dessanti ML; Pisani F; Vignally P; Petti MC
    Scand J Infect Dis; 2012 Jan; 44(1):70-3. PubMed ID: 21905952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
    Ignatova TM; Mukhin NA
    Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of low-grade non-Hodgkin's lymphoma after treatment with pegylated interferon plus ribavirin in hepatitis C virus infection.
    Mazzaro C; Spina M; Tirelli U
    J Clin Oncol; 2005 Jul; 23(19):4470-1; author reply 4471. PubMed ID: 15994165
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
    Terrier B; Saadoun D; Sène D; Sellam J; Pérard L; Coppéré B; Karras A; Blanc F; Buchler M; Plaisier E; Ghillani P; Rosenzwajg M; Cacoub P
    Arthritis Rheum; 2009 Aug; 60(8):2531-40. PubMed ID: 19644879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.
    Hermine O; Lefrère F; Bronowicki JP; Mariette X; Jondeau K; Eclache-Saudreau V; Delmas B; Valensi F; Cacoub P; Brechot C; Varet B; Troussard X
    N Engl J Med; 2002 Jul; 347(2):89-94. PubMed ID: 12110736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon.
    Mauro E; Pedata M; Ermacora A; Mazzaro C
    Blood Transfus; 2012 Jan; 10(1):101-3. PubMed ID: 21839019
    [No Abstract]   [Full Text] [Related]  

  • 9. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents.
    Carrier P; Jaccard A; Jacques J; Tabouret T; Debette-Gratien M; Abraham J; Mesturoux L; Marquet P; Alain S; Sautereau D; Essig M; Loustaud-Ratti V
    Liver Int; 2015 Oct; 35(10):2222-7. PubMed ID: 26104059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.
    Odolini S; Lanza P; Angiola A; Zaltron S; Urbinati L; Vavassori A; Nasta P; Festa E; Gargiulo F; Rodella A; Caruso A; Casari S; Castelli F; Viganò M
    New Microbiol; 2017 Jul; 40(3):218-220. PubMed ID: 28513813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.
    Kelaidi C; Rollot F; Park S; Tulliez M; Christoforov B; Calmus Y; Podevin P; Bouscary D; Sogni P; Blanche P; Dreyfus F
    Leukemia; 2004 Oct; 18(10):1711-6. PubMed ID: 15284859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience.
    Vallisa D; Bernuzzi P; Arcaini L; Sacchi S; Callea V; Marasca R; Lazzaro A; Trabacchi E; Anselmi E; Arcari AL; Moroni C; Bertè R; Lazzarino M; Cavanna L
    J Clin Oncol; 2005 Jan; 23(3):468-73. PubMed ID: 15659492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?
    Luppi M; Barozzi P; Potenza L; Riva G; Morselli M; Torelli G
    Leukemia; 2004 Oct; 18(10):1572-5. PubMed ID: 15284857
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.
    Mihăilă RG
    World J Gastroenterol; 2016 Jul; 22(27):6214-23. PubMed ID: 27468211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon Alfa.
    Levine AM; Shimodaira S; Lai MM
    N Engl J Med; 2003 Nov; 349(21):2078-9. PubMed ID: 14627800
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.
    Merli M; Carli G; Arcaini L; Visco C
    World J Gastroenterol; 2016 Oct; 22(38):8447-8458. PubMed ID: 27784957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment.
    Thomopoulos K; Giannakoulas NC; Tsamandas AC; Mimidis K; Fragopanagou E; Pallasopoulou M; Lampropoulou-Karatza Ch
    Am J Med Sci; 2008 Jul; 336(1):73-6. PubMed ID: 18626242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
    Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
    Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII inhibitor associated with peginterferon.
    Herman C; Boggio L; Green D
    Haemophilia; 2005 Jul; 11(4):408-10. PubMed ID: 16011596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.